Bioinformatics Reveal RIPK1's Role in Clear Cell Renal Cell Carcinoma
Overview
This study systematically characterizes RIPK1's biological function and clinical significance in clear cell renal cell carcinoma (ccRCC). Using large-scale bioinformatics analyses and in vitro experiments, RIPK1 was shown to influence tumor cell proliferation and invasion, establishing it as a promising prognostic biomarker and therapeutic target.
Background
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 80% of cases. Despite advances in treatment, prognosis remains poor in advanced stages, highlighting the need for novel biomarkers and therapeutic targets. Programmed cell death, particularly necroptosis mediated by proteins such as RIPK1, plays a crucial role in tumor progression. However, the specific role and mechanisms of RIPK1 in ccRCC have not been fully elucidated.
Data Highlights
Dataset
Sample Type
Sample Size
RIPK1 Expression
Diagnostic Performance (ROC)
TCGA-ccRCC
ccRCC vs Normal
535 ccRCC, 72 Normal
Significantly elevated in ccRCC
High diagnostic accuracy
GSE53757
ccRCC vs Normal
72 ccRCC, 72 Normal
Elevated in ccRCC
High diagnostic accuracy
GSE66272
ccRCC vs Normal
27 ccRCC, 27 Normal
Elevated in ccRCC
High diagnostic accuracy
E-MTAB-1980
ccRCC Survival Data
101 ccRCC patients
Prognostic value validated
Kaplan-Meier survival differences observed
Key Findings
RIPK1 expression is significantly upregulated in ccRCC tissues compared to normal kidney tissues across multiple independent datasets.
High RIPK1 expression correlates with poorer overall survival in ccRCC patients, confirmed by Kaplan-Meier analyses.
Functional enrichment and regulatory network analyses suggest RIPK1 involvement in cell proliferation, invasion, and necroptosis pathways.
In vitro silencing of RIPK1 in ccRCC cell lines reduces cell proliferation and invasion, indicating a functional role in tumor progression.
RIPK1 serves as a robust diagnostic biomarker with high accuracy in distinguishing ccRCC from normal tissue.
A diagnostic nomogram incorporating RIPK1 expression and clinical features was developed to improve ccRCC patient stratification.
Clinical Implications
RIPK1 represents a promising prognostic biomarker for ccRCC, aiding in risk stratification and potentially guiding therapeutic decisions. Targeting RIPK1-mediated pathways may offer novel treatment strategies to inhibit tumor growth and invasion. Incorporation of RIPK1 expression into diagnostic models can enhance early detection and improve patient management.
Conclusion
This comprehensive bioinformatics and experimental study establishes RIPK1 as a key mediator in ccRCC progression with significant prognostic and diagnostic value. These findings provide a foundation for future translational research targeting RIPK1 in ccRCC therapy.
References
Tang X et al. 2019 -- RIPK1 silencing induces apoptosis in RCC cells
